Vaccine Made From Mosquito Saliva Protein Safe In Humans, Triggers Antibody Responses, Aims To Be First Universal Vaccine For Mosquito-Borne Illnesses

Reuters: How a vaccine made of mosquito spit could help stop the next epidemic
“…Building on the work of colleagues and other scientists, [Jessica] Manning, a clinical researcher for the U.S. National Institute of Allergy and Infectious Diseases, believed she could use pieces of mosquito saliva protein to build a universal vaccine. The vaccine, if it pans out, would protect against all of the pathogens the insects inject into humans — malaria, dengue, chikungunya, Zika, yellow fever, West Nile, Mayaro viruses, and anything else that may emerge. … On Thursday, The Lancet published the initial results of this work with her colleagues: the first-ever clinical trial of a mosquito spit vaccine in humans. The trial showed that an Anopheles mosquito-based vaccine was safe and that it triggered antibody and cellular responses…” (Baldwin, 6/11).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.